Libera Bio founder and Chief Scientific Officer Maria Alonso talks to Proactive about some of the key benefits surrounding the group's proprietary MPN encapsulation technology to help fight cancer.
The nanotechnology targets tumor and metastatic cells and delivers small and large molecules to intracellular targets. Alonso says the group has validated the technology with Proof-of-Concept studies, and is now co-developing its first two assets.